RT Journal Article
SR Electronic
T1 New therapies for type 2 diabetes based on glucagon-like peptide 1
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 382
OP 389
VO 73
IS 4
A1 Salehi, Marzieh
A1 D’alessio, David A.
YR 2006
UL http://www.ccjm.org/content/73/4/382.abstract
AB Cells in the gastrointestinal tract secrete several hormones that stimulate insulin secretion, one of which is glucagon-like peptide (GLP-1). Several new drugs act through the GLP-1 signaling system to stimulate insulin release and regulate blood glucose levels in patients with diabetes. One such compound, exenatide (Byetta), has recently become available, and others are in clinical development.